(Bold for FDA approved)
How Stride works• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Blocks dopamine 3 and 4 receptors, which may contribute to sulpiride’s actions
• Possibly blocks presynaptic dopamine 2 autoreceptors more potently at low doses, which could theoretically contribute to improving negative symptoms of schizophrenia as well as depression
• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior
Notable Side Effects• Drug-induced parkinsonism, akathisia
• Prolactin elevation, galactorrhea, amenorrhea
• Sedation, dizziness, sleep disturbance, headache, impaired concentration
• Dry mouth, nausea, vomiting, constipation, anorexia
• Impotence
• Tardive dyskinesia
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Rare hypomania
• Palpitations, hypertension
• Weight gain
Life Threatening Side Effects• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Rare seizures
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis

common

common
• Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Reduce the dose
• For sedation, give at night
• Switch to an atypical antipsychotic
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• Schizophrenia: 400–800 mg/day in 2 doses (oral)
• Predominantly negative symptoms: 50–300 mg/day (oral)
• Intramuscular injection: 600–800 mg/day
• Depression: 150–300 mg/day (oral)
Dosage Forms• Different formulations may be available in different markets
• Tablet 200 mg, 400 mg, 500 mg
• Intramuscular injection 50 mg/mL, 100 mg/mL
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• No
Renal Impairment• Use with caution; drug may accumulate
• Sulpiride is eliminated by the renal route; in cases of severe renal insufficiency, the dose should be decreased and intermittent treatment or switching to another antipsychotic should be considered
Hepatic Impairment• Use with caution
Cardiac Impairment• Use with caution
Elderly• Some patients may tolerate lower doses better
• Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
Children and Adolescents• Not recommended for use in children under age 15
• 14 and older: recommended 3–5 mg/kg per day
Pregnancy• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Potential risks should be weighed against the potential benefits, and sulpiride should be used only if deemed necessary
• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary
• Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy
Breast Feeding• Some drug is found in mother’s breast milk
• Recommended either to discontinue drug or bottle feed
• Immediate postpartum period is a high-risk time for relapse of psychosis
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera